2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Ahmed Maseh Haidary ◽  
Sarah Noor ◽  
Esmatullah Hamed ◽  
Tawab Baryali ◽  
Soma Rahmani ◽  
...  

Abstract Introduction The novel coronavirus, since its first identification in China, in December 2019, has shown remarkable heterogeneity in its clinical behavior. It has affected humans on every continent. Clinically, it has affected every organ system. The outcome has also been variable, with most of the older patients showing grave outcomes as compared with the younger individuals. Here we present a rare and severe variant of Guillain–Barre syndrome that complicated the disease in recovery phase. Case presentation A 60-year-old Afghan man, who had been recovering from symptoms related to novel coronavirus associated disease, presented with sudden onset of progressive muscle weakness and oxygen desaturation. Electrophysiological workup confirmed the diagnosis of Guillain–Barre syndrome, and early institution of intravenous immunoglobulin resulted in complete resolution. Conclusion Guillain–Barre syndrome has recently been reported in many patients diagnosed with novel coronavirus associated disease. While clinical suspicion is mandatory to guide towards an effective diagnostic workup, early diagnosis of this complication and timely institution of therapeutic interventions are indispensable and lifesaving.


Author(s):  
Akhmadeeva L.R. ◽  
Izhbuldina E.V. ◽  
Khayrullin A.T.

In this paper, various neuromuscular manifestations of coronavirus infection are considered and methods of damage to the nervous system are highlighted. These include the "cytokine storm", impaired hemostasis, neurotropicity and neurovirulence of SARS-CoV-2. The persistence of the virus in the body affects the course of comorbid diseases, which requires a systematic approach to patient treatment. In this paper we discuss the data from modern research papers and clinical cases both from updated international literature and from our own clinical practice: it is the most frequently met condition - Guillain-Barré syndrome – acute inflammatory demyelinating polyneuropathy. We present both rare and common neuro-muscular conditions, their clinical onset, possible pathogenesis, variants of manifestation. According to the data from current publications, the evaluation and management of patients suffering from Guillain-Barré syndrome associated with new coronaviral infection SARS-CoV-2 is does not have major differences with the classical ones, that are not associated with the pandemic. Our patient that we present as our own case, was hospitalized, and observed as an in-patient. She was treated using plasma exchange in the algorithm of management. The outcome of this case was positive. We conclude that neuromuscular manifestation of new coronaviral infection SARS-CoV-2 could be new and possibly associated with this disease, but also could be described as worsening of the premorbid disorders. For instance, inherited neuromuscular diseases could have different variants during the period of pandemic caused by novel coronavirus SARS-CoV-2 infection.


2001 ◽  
Vol 13 (5) ◽  
pp. 575-577 ◽  
Author(s):  
L. Calza ◽  
R. Manfredi ◽  
G. Marinacci ◽  
E. Briganti ◽  
R. Giuliani S. Talo' ◽  
...  

2020 ◽  
Vol 13 (8) ◽  
pp. e236419 ◽  
Author(s):  
Amanda Ray

Beyond the typical respiratory symptoms and fever associated with severe acute respiratory syndrome, we may still have much to learn about other manifestations of the novel SARS-CoV-2 infection. A patient presented with Guillain-Barré syndrome in China with a concurrent SARS-CoV-2 infection. The following case report looks at a patient presenting with the rare Miller Fisher syndrome, a variant of Guillain-Barré while also testing positive for COVID-19.


2016 ◽  
Vol 88 (5) ◽  
pp. 79 ◽  
Author(s):  
D. A. Degterev ◽  
N. A. Suponeva ◽  
N. A. Bodunova ◽  
М. V. Voronova ◽  
Е. A. Zorin ◽  
...  

2017 ◽  
Vol 381 ◽  
pp. 278-279
Author(s):  
N. Hamza ◽  
O. Hdiji ◽  
H. Haj Kacem ◽  
N. Farhat ◽  
M. Dammak ◽  
...  

2020 ◽  
pp. 10.1212/CPJ.0000000000000879 ◽  
Author(s):  
Seyed Amir Ebrahimzadeh ◽  
Abdoreza Ghoreishi ◽  
Nasrin Rahimian

In December 2019, the first case of pneumonia with unknown etiology was reported in Wuhan city, China. The identified pathogen was a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).1 Since then, the virus has spread rapidly worldwide. Although Coronavirus disease 2019 (COVID-19) typically presents with upper or lower respiratory symptoms, there have been rare reports of significant neurologic complications.2,3 Recently, a few reports presented cases of Guillain-Barré syndrome (GBS) after COVID-19.4,5 In this report, we describe 2 cases of GBS that occurred following COVID-19.


Author(s):  
Cenk Gokalp ◽  
Cagla Yildiz ◽  
Busra Tunc ◽  
Ilhan Kurultak ◽  
Sedat Ustundag

2020 ◽  
Vol 21 (4) ◽  
pp. 240-242 ◽  
Author(s):  
Sandeep Rana ◽  
Arthur A. Lima ◽  
Rahul Chandra ◽  
James Valeriano ◽  
Troy Desai ◽  
...  

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Jian Chen ◽  
Jian-xiong Ma ◽  
Cai-hong Zuo ◽  
Qing Zhang ◽  
Heng-ting Chen ◽  
...  

Abstract Background Guillain-Barré syndrome (GBS) is the most common and serious acute paralytic neuropathy and is usually caused by infection. It is thought to be the result of an aberrant response of the immune system. To our knowledge, GBS, especially severe GBS, after orthopaedic surgery has rarely been reported. Case presentation We herein report the case of a 58-year-old man who developed quadriplegia and respiratory failure on the 6th day after surgery for multiple fractures. The patient had no symptoms of respiratory or gastrointestinal tract infection within 4 weeks before the onset. The white blood cell count was normal, and there was no redness, swelling, heat or pain in the surgical incision. Brain, cervical and thoracic magnetic resonance imaging were normal, albuminocytological dissociation was found on cerebrospinal fluid examination, and electrophysiological examination showed that sensory and motor nerve evoked potentials could not be elicited. A diagnosis of post-traumatic GBS was made, and the patient was treated with intravenous immunoglobulin and plasma exchange, as well as supportive care and rehabilitation exercise. The length of stay was 18 months, and the in-hospital-related costs amounted to $127,171. At the last follow-up, the patient had recovered only grade 3 power in the upper limbs and grade 2 power in the lower limbs. Conclusions Severe GBS is a rare complication after orthopaedic surgery. When progressive weakness occurs in trauma patients, the possibility of GBS should be considered, and cerebrospinal fluid and electrophysiological examinations should be performed in a timely manner. For patients with severe GBS after trauma, the treatment costs may be high, and the prognosis may be poor.


Sign in / Sign up

Export Citation Format

Share Document